Compare Gilead Sciences, Inc. (GILD) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Schwab US Dividend Equity ETF — how do they compare? Gilead Sciences, Inc. trades at $150.63 (market cap $182.40B), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| GILD | SCHD | |
|---|---|---|
Market Cap | $182.40B | $110.56B |
Volume | 4,469,821 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $35.21 |
52-Week Low | $116.74 | $26.44 |
Typical Hold Time | 111 Days | 62 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
SCHD trades at $33.06, up 1.26% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 in 2026, with recent news highlighting its dividend growth and defensive positioning. Key support sits at $32 with resistance at $34, while oscillators show neutral momentum. The fund's rules-based approach focuses on high-quality dividend stocks, though recent exclusions like Broadcom have sparked discussion about opportunity costs.
SCHD offers income investors exposure to rising dividends with lower fees, but faces headwinds from interest rate sensitivity and strict selection criteria that may limit growth participation. The current pullback from August highs near $35 presents a potential entry point for dividend-focused portfolios seeking quality and yield sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
